Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed th
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker
08:58am, Saturday, 28'th Feb 2026
Acadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE, are guided to continue their strong growth trajectories. These two drugs alone support a "buy" thesis for Acadia. Learning from previou
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
10:56am, Thursday, 26'th Feb 2026
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
01:57am, Thursday, 26'th Feb 2026
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
08:25pm, Wednesday, 25'th Feb 2026
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.17 per share a year ago.
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
04:05pm, Wednesday, 25'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. “Acadia closed 2025 with a
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Monday, 23'rd Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fi
Rhumbline Advisers Buys 24,463 Shares of ACADIA Pharmaceuticals Inc. $ACAD
04:48am, Sunday, 22'nd Feb 2026
Rhumbline Advisers boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 6.7% during the third quarter, according to the company in its most recent filing with the Securities
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Wednesday, 18'th Feb 2026
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by GSA Capital Partners LLP
05:20am, Wednesday, 18'th Feb 2026
GSA Capital Partners LLP raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 210.1% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned
LSV Asset Management Sells 192,800 Shares of ACADIA Pharmaceuticals Inc. $ACAD
04:03am, Wednesday, 18'th Feb 2026
LSV Asset Management decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 91.8% during the undefined quarter, according to the company in its most recent filing with the SEC. The fu
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:44am, Friday, 06'th Feb 2026
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty ratings firms that are covering the firm, MarketBeat Rati
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
04:05pm, Wednesday, 04'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after th
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
11:02am, Tuesday, 03'rd Feb 2026
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
10:00am, Tuesday, 03'rd Feb 2026
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp
